EU/3/00/013: Orphan designation for the treatment of Huntington’s disease

Ethyl Eicosapentaenoate

Table of contents

Overview

On 29 December 2000, orphan designation (EU/3/00/013) was granted by the European Commission to Laxdale Ltd., United Kingdom, for ethyl eicosopentaenoate for the treatment of Huntington's disease. The name of the sponsor has since changed to Amarin Neuroscience Ltd.

Key facts

Active substance
Ethyl Eicosapentaenoate
Intented use
Treatment of Huntington’s disease
Orphan designation status
Positive
EU designation number
EU/3/00/013
Date of designation
29/12/2000
Sponsor
Amarin Neuroscience Ltd
Kings Park House
Laurelhill Business Park
STIRLING FK7 9JQ
United Kingdom
Telephone: +44 17 86 47 60 00
Telefax: +44 17 86 47 31 37
E-mail: admin@amarin-neuro.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating